Natural Products Insider is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
HomeBusiness ResourcesBusiness OperationsLabs/TestingChromaDex Announces Top Line Results of its Second Human Clinical Trial

ChromaDex Announces Top Line Results of its Second Human Clinical Trial

<p>ChromaDex Corp. (NASDAQ:CDXC announced today that the initial results of its second human clinical study of NIAGEN<sup>&reg;</sup> nicotinamide riboside chloride (NR) have confirmed NR significantly and sustainably raises the co-enzyme nicotinamide adenine dinucleotide (NAD+) in 140 healthy human volunteers over 8-weeks.</p>
TAGS: Healthy Living Ingredients Business Resources
Hide comments
account-default-image
user not logged in

More information about text formats

Comments

  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Publish
Related
curcumin ingredient.jpg
Supply chain considerations for curcumin
Dec 12, 2022
Female scientists.jpg
SupplySide West conversation focuses on women in nutraceuticals research lab
Dec 05, 2022
CBD oil containers
Undisclosed THC threatens CBD market
Aug 04, 2022
U.S. Hemp Authority Seal
Hemp quality standards cut delta-8 THC from consideration
Jun 05, 2022